Your browser doesn't support javascript.
loading
Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase.
Chen, Qingqing; Xia, Yu; Liu, He-Nan; Chi, Yuan; Li, Xun; Shan, Li-Shen; Dai, Bing; Zhu, Ying; Wang, Ya-Tao; Miao, Xinxin; Sun, Qian.
Afiliação
  • Chen Q; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Xia Y; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Liu HN; Shengjing Hospital of China Medical University, Shenyang, China.
  • Chi Y; Shengjing Hospital of China Medical University, Shenyang, China.
  • Li X; Shengjing Hospital of China Medical University, Shenyang, China.
  • Shan LS; Shengjing Hospital of China Medical University, Shenyang, China.
  • Dai B; Shengjing Hospital of China Medical University, Shenyang, China.
  • Zhu Y; Department of Neurology, The First Hospital of China Medical University, Shenyang, China.
  • Wang YT; Rega Institute for Medical Research, Medicinal Chemistry, KU Leuven, Herestraat 49-Box 1041, 3000, Leuven, Belgium. Electronic address: yataowangjlu@outlook.com.
  • Miao X; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: mxxcmu9311@163.com.
  • Sun Q; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: claire_sq@sina.com.
Eur J Med Chem ; 277: 116769, 2024 Nov 05.
Article em En | MEDLINE | ID: mdl-39163778
ABSTRACT
Phosphodiesterases (PDEs) constitute a family of enzymes that play a pivotal role in the regulation of intracellular levels of cyclic nucleotides, including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Dysregulation of PDE activity has been implicated in diverse pathological conditions encompassing cardiovascular disorders, pulmonary diseases, and neurological disorders. Small-molecule inhibitors targeting PDEs have emerged as promising therapeutic agents for the treatment of these ailments, some of which have been approved for their clinical use. Despite their success, challenges such as resistance mechanisms and off-target effects persist, urging continuous research for the development of next-generation PDE inhibitors. The objective of this review is to provide an overview of the synthesis and clinical application of representative approved small-molecule PDE inhibitors, with the aim of offering guidance for further advancements in the development of novel PDE inhibitors.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Fosfodiesterase / Diester Fosfórico Hidrolases / Bibliotecas de Moléculas Pequenas Limite: Animals / Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Fosfodiesterase / Diester Fosfórico Hidrolases / Bibliotecas de Moléculas Pequenas Limite: Animals / Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: França